WO2010024138A1 - エピガロカテキンガレート重合体を有効成分とするグルコシルトランスフェラーゼ阻害剤 - Google Patents
エピガロカテキンガレート重合体を有効成分とするグルコシルトランスフェラーゼ阻害剤 Download PDFInfo
- Publication number
- WO2010024138A1 WO2010024138A1 PCT/JP2009/064335 JP2009064335W WO2010024138A1 WO 2010024138 A1 WO2010024138 A1 WO 2010024138A1 JP 2009064335 W JP2009064335 W JP 2009064335W WO 2010024138 A1 WO2010024138 A1 WO 2010024138A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- glucosyltransferase
- trimer
- egcg
- epigallocatechin gallate
- Prior art date
Links
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 title claims abstract description 74
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 title claims abstract description 65
- 229940122959 Glucosyltransferase inhibitor Drugs 0.000 title claims abstract description 22
- 229940030275 epigallocatechin gallate Drugs 0.000 title claims abstract description 20
- 239000004480 active ingredient Substances 0.000 title claims description 14
- 229920000642 polymer Polymers 0.000 title abstract description 26
- 150000001875 compounds Chemical class 0.000 claims abstract description 68
- 230000000170 anti-cariogenic effect Effects 0.000 claims abstract description 17
- 239000004091 cariogenic agent Substances 0.000 claims abstract description 16
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 239000013638 trimer Substances 0.000 claims description 30
- 235000013305 food Nutrition 0.000 claims description 22
- 239000013589 supplement Substances 0.000 claims description 14
- 235000013616 tea Nutrition 0.000 claims description 11
- 235000013361 beverage Nutrition 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000004075 cariostatic agent Substances 0.000 claims description 6
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical group C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 claims description 6
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 abstract 1
- 108010055629 Glucosyltransferases Proteins 0.000 description 43
- 102000000340 Glucosyltransferases Human genes 0.000 description 43
- 230000002401 inhibitory effect Effects 0.000 description 27
- 230000000694 effects Effects 0.000 description 22
- 229920001503 Glucan Polymers 0.000 description 16
- 235000006468 Thea sinensis Nutrition 0.000 description 15
- 244000269722 Thea sinensis Species 0.000 description 14
- FKRUMFFNBGSGGM-MIYUYXAISA-N Oolonghomobisflavan B Natural products O=C(O[C@H]1[C@H](c2cc(O)c(O)c(O)c2)Oc2c(Cc3c(O)c4c(O[C@@H]([C@H](OC(=O)c5cc(O)c(O)c(O)c5)C4)c4cc(O)c(O)c(O)c4)cc3O)c(O)cc(O)c2C1)c1cc(O)c(O)c(O)c1 FKRUMFFNBGSGGM-MIYUYXAISA-N 0.000 description 13
- FKRUMFFNBGSGGM-UHFFFAOYSA-N oolonghomobisflavan b Chemical compound OC1=C(O)C(O)=CC(C2C(CC3=C(O)C(CC=4C=5OC(C(OC(=O)C=6C=C(O)C(O)=C(O)C=6)CC=5C(O)=CC=4O)C=4C=C(O)C(O)=C(O)C=4)=C(O)C=C3O2)OC(=O)C=2C=C(O)C(O)=C(O)C=2)=C1 FKRUMFFNBGSGGM-UHFFFAOYSA-N 0.000 description 13
- 108010017836 1,3-alpha-D-glucan synthase Proteins 0.000 description 12
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 12
- 235000020333 oolong tea Nutrition 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 108010076450 glucosyltransferase C Proteins 0.000 description 11
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 208000002925 dental caries Diseases 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 238000005481 NMR spectroscopy Methods 0.000 description 9
- 241000194019 Streptococcus mutans Species 0.000 description 8
- 229940125782 compound 2 Drugs 0.000 description 8
- 229940126214 compound 3 Drugs 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- BJFGFQSYHAXQPO-YUTGENNUSA-N oolong homobisflavan A Natural products O=C(O[C@@H]1[C@H](c2cc(O)c(O)c(O)c2)Oc2c(Cc3c(O)cc(O)c4c3O[C@@H]([C@H](OC(=O)c3cc(O)c(O)c(O)c3)C4)c3cc(O)c(O)c(O)c3)c(O)cc(O)c2C1)c1cc(O)c(O)c(O)c1 BJFGFQSYHAXQPO-YUTGENNUSA-N 0.000 description 8
- BJFGFQSYHAXQPO-UHFFFAOYSA-N oolonghomobisflavan a Chemical compound OC1=C(O)C(O)=CC(C2C(CC3=C(O)C=C(O)C(CC=4C=5OC(C(OC(=O)C=6C=C(O)C(O)=C(O)C=6)CC=5C(O)=CC=4O)C=4C=C(O)C(O)=C(O)C=4)=C3O2)OC(=O)C=2C=C(O)C(O)=C(O)C=2)=C1 BJFGFQSYHAXQPO-UHFFFAOYSA-N 0.000 description 8
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 7
- 235000005487 catechin Nutrition 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 150000001765 catechin Chemical class 0.000 description 6
- 229940125904 compound 1 Drugs 0.000 description 6
- 229930003935 flavonoid Natural products 0.000 description 6
- 235000017173 flavonoids Nutrition 0.000 description 6
- 150000002215 flavonoids Chemical class 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- ZSDSQXJSNMTJDA-UHFFFAOYSA-N trifluralin Chemical compound CCCN(CCC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O ZSDSQXJSNMTJDA-UHFFFAOYSA-N 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 5
- 210000000214 mouth Anatomy 0.000 description 5
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 5
- 235000019629 palatability Nutrition 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 230000000675 anti-caries Effects 0.000 description 4
- 244000309464 bull Species 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010006326 Breath odour Diseases 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 235000009569 green tea Nutrition 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- WMBWREPUVVBILR-GHTZIAJQSA-N (+)-gallocatechin gallate Chemical compound O([C@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-GHTZIAJQSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 235000020279 black tea Nutrition 0.000 description 2
- 150000001793 charged compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000012581 double quantum filtered COSY Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000019225 fermented tea Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 2
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002552 multiple reaction monitoring Methods 0.000 description 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 235000021055 solid food Nutrition 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000012916 structural analysis Methods 0.000 description 2
- 238000001551 total correlation spectroscopy Methods 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 0 Cc(c(O[C@@]([C@](C1)O*)c(cc2O)cc(O)c2O)c1c(O)c1)c1O Chemical compound Cc(c(O[C@@]([C@](C1)O*)c(cc2O)cc(O)c2O)c1c(O)c1)c1O 0.000 description 1
- 241001640558 Cotoneaster horizontalis Species 0.000 description 1
- 208000002064 Dental Plaque Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000051366 Glycosyltransferases Human genes 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- 108010022337 Leucine Enkephalin Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- WQGWDDDVZFFDIG-UHFFFAOYSA-N Oc1cccc(O)c1O Chemical compound Oc1cccc(O)c1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000193987 Streptococcus sobrinus Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 239000000551 dentifrice Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002206 flavan-3-ols Chemical class 0.000 description 1
- 235000011987 flavanols Nutrition 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- 150000002208 flavanones Chemical class 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- URLZCHNOLZSCCA-UHFFFAOYSA-N leu-enkephalin Chemical compound C=1C=C(O)C=CC=1CC(N)C(=O)NCC(=O)NCC(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=CC=C1 URLZCHNOLZSCCA-UHFFFAOYSA-N 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
- C07D311/62—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Definitions
- the present invention relates to a glucosyltransferase inhibitor containing an epigallocatechin gallate polymer as an active ingredient, and a food or drink to which this is added.
- the caries generation mechanism is as follows.
- the oral streptococci especially Streptococcus mutans (Streptococcus mutans, hereinafter referred to as "S ⁇ mutans”.
- Glucosyltransferase which is produced (glycosyltransferase, GTF) is, the mouth of sucrose as the substrate, the pressure-sensitive adhesive It produces sex-insoluble polysaccharides (glucans).
- GTF glycose
- mutans adhere to the tooth surface by the generated glucan to form a bacterial mass (plaque).
- various microorganisms such as S. mutans coexist and proliferate, but organic acids are produced by the metabolism of these microorganisms, and the pH inside the plaque is lowered by the action of these organic acids, and tooth enamel Decalcification occurs on the surface of the material, causing caries and progressing. Plaque formation is considered to cause periodontal disease and bad breath in addition to caries.
- the plaque formed by oral streptococci centered on S. mutans causes caries, it is effective to suppress the formation of dental plaque and thus prevent the occurrence of caries. It can be a means.
- Patent Document 1 discloses that a flavonoid polymer having a molecular weight of 800 to 5000 produced by treating a flavonoid (a kind of catechin) with peroxidase has an enhanced inhibitory action on glucosyltransferase as compared with that before the treatment. It has been reported.
- Non-Patent Document 1 reports that a flavonoid polymer inhibits the activity of a glucosyltransferase derived from Streptococcus sobrinus by 50% at 2.5 ⁇ g / mL.
- Patent Document 2 discloses that a flavonoid polymer having a weight molecular weight of 1000 to 10,000 produced by condensing reduced products of flavanones / flavanols or leucocyanidines with catechins has an inhibitory action on glucosyltransferase. Has been reported.
- these flavonoid polymers are a mixture of flavonoids in a 3 to 5 mer or a mixture of 2 to 3 mers, and various compounds contained in the mixture have not been isolated.
- the glucosyltransferase inhibitory activity for each of the simple substances has not been clarified.
- Non-Patent Document 2 It has been reported that among edible teas, a mixture of catechins derived from green tea, which is non-fermented tea, has a glucosyltransferase inhibitory effect (Non-Patent Document 2). However, it has also been reported that sufficient anti-caries activity was not obtained in a test using rats.
- Patent Document 3 Non-Patent Document 3, Non-Patent Document 4, and Non-Patent Document 5
- Patent Document 4 heat treatment of green tea, oolong tea, and black tea enhances glucosyltransferase inhibitory activity
- Patent Document 5 heat treatment of catechins enhances glucosyltransferase inhibitory activity.
- JP-A-6-247959 Japanese Patent Laid-Open No. 7-242556 JP-A-6-279302 JP-A-3-284625 JP-A-3-284671
- the inventors of the present invention have intensively studied paying attention to the components contained in tea that is drunk daily, considering that it is used as a food and drink, and are a kind of catechins contained in oolong tea ( ⁇ )-epi.
- the EGCG polymer obtained by polymerizing gallocatechin-3-O-gallate (hereinafter also referred to as EGCG) has been found to have a strong glucosyltransferase inhibitory activity, particularly to the EGCG trimer, leading to the present invention. It was.
- the present invention is as follows. 1. A glucosyltransferase inhibitor comprising epigallocatechin gallate trimer or a salt thereof as an active ingredient. 2. 2. The glucosyltransferase inhibitor according to 1 above, wherein the epigallocatechin gallate trimer is a compound bonded via a methylene group at the 6-position and / or 8-position of the chroman ring. 3.
- the epigallocatechin gallate trimer has the following formula (I):
- R represents the following formula (A):
- the glucosyltransferase inhibitor which uses the compound represented by these as an active ingredient. 5).
- An anti-cariogenic agent comprising epigallocatechin gallate trimer or a salt thereof as an active ingredient. 6).
- 6. The anticaries agent according to 5 above, wherein the epigallocatechin gallate trimer is a compound bonded via a methylene group at the 6-position and / or 8-position of the chroman ring. 7).
- the epigallocatechin gallate trimer is a compound having the formula (I), a compound having the formula (II), and a compound having the formula (III) (in the formulas (I) to (III), R is 7.
- the anti-cariogenic agent according to 6 above which is a compound selected from the group consisting of: a galloyl group represented by the formula (A). 8).
- An anticaries agent comprising the compound represented by the formula (IV) as an active ingredient.
- a food or drink to which the glucosyltransferase inhibitor or anti-cariogenic agent according to any one of 1 to 8 above is added.
- 10. The food or drink according to 9 above, wherein the food or drink is a tea drink.
- the present inventors have found that ( ⁇ )-epigallocatechin-3-O-gallate (EGCG) polymers, particularly specific EGCG dimers and trimers, have a high glucosyltransferase inhibitory action. It was. As described above, glucosyltransferase (hereinafter also referred to as GTF) produces glucan that causes plaque in the mouth, and thus caries can be prevented by inhibiting the activity of GTF. Therefore, the GTF inhibitor of the present invention can be used as an anticaries agent. Moreover, since the GTF inhibitor of this invention suppresses the production
- GTF glucosyltransferase
- the GTF inhibitor of the present invention is derived from EGCG contained in foods and drinks for daily eating and drinking such as oolong tea, it has high palatability and high safety for the human body. Moreover, by containing a certain amount of this GTF inhibitor in a food or drink, it is possible to provide a food or drink having a high palatability and a safe anti-cariogenic effect without excessively impairing the flavor of the food or drink.
- FIG. 1 shows the 1 HNMR spectrum of compound 2.
- FIG. 2 shows the 13 C NMR spectrum of compound 2.
- FIG. 3 shows the 1 HNMR spectrum of compound 3.
- FIG. 4 shows the 13 C NMR spectrum of compound 3.
- FIG. 5 shows the 1 HNMR spectrum of Compound 1.
- FIG. 6 shows the 13 C NMR spectrum of Compound 1.
- FIG. 7 shows the evaluation results of the inhibitory action on glucosyltransferase B of each compound of EGCG dimer and trimer.
- FIG. 8 shows the evaluation results of the inhibitory action on the glucosyltransferase C of each compound of EGCG dimer and trimer.
- FIG. 9 shows the evaluation results of the inhibitory action on glucosyltransferase B of each compound of EGCG trimer and tetramer.
- FIG. 10 shows the evaluation results of the inhibitory action on the glucosyltransferase C of each compound of EGCG trimer and tetramer.
- EGCG Epicocacatechin-3-O-gallate
- the active ingredient contained in the GTF inhibitor of the present invention is the EGCG polymer.
- an EGCG polymer having a structure in which two or three EGCGs are bonded via the methylene group at the 6-position and / or 8-position of the chroman ring can be preferably used.
- Specific examples of such EGCG polymers include the following formulas (I), (II), and (III):
- the compound of formula (I) can be represented as EGCG8: 8EGCG6: 8EGCG based on the binding mode of EGCG (hereinafter referred to as oolong homobisflavan-trimer-1, OHBF-Tri-1, Or called Tri-1).
- the compound of the formula (II) can be expressed as EGCG6: 8EGCG6: 8EGCG (hereinafter referred to as oolong homobisflavan-trimer-2, OHBF-Tri-2, or Tri-2). Called).
- the compound of the formula (III) can be represented as EGCG8: 8EGCG6: 6EGCG (hereinafter referred to as oolong homobisflavan-trimer-4, OHBF-Tri-4, or Tri-4 in this specification). ).
- the compound of formula (IV) can be expressed as EGCG6: 8EGCG.
- the compound of formula (IV) is reported to be a compound contained in oolong tea and the like, and is known as oolong homobisflavan-B (OHBF-B).
- the compounds of formulas (II) and (III) are novel compounds.
- the above EGCG polymer can be produced by reacting epigallocatechin gallate with formaldehyde in a solvent in the presence of an acid.
- Examples of the solvent that can be used for the reaction include alcohols such as methanol, ethanol, n-propanol, and isopropanol.
- the amount of the solvent used is not particularly limited. For example, 20 to 200 parts by mass of the solvent can be used with respect to 1 part by mass of epigallocatechin gallate.
- the acid for example, inorganic acids such as hydrochloric acid, sulfuric acid, and nitric acid, and organic acids such as formic acid and acetic acid can be used.
- the amount of acid used is not particularly limited. For example, 0.01 to 2 mol of acid can be used per 1 mol of epigallocatechin gallate.
- Formaldehyde can be used, for example, in an amount of 1 to 100 mol with respect to 1 mol of EGCG.
- the reaction temperature and time may vary depending on the amount of solvent used, etc.
- the reaction temperature is ⁇ 10 to 50 ° C.
- the reaction time is 10 minutes to 12 hours.
- the reaction temperature is room temperature (about 25 ° C.).
- the product obtained by the reaction of EGCG and formaldehyde is usually a mixture containing at least two compounds of different compounds in which the chroman ring is linked by a methylene group.
- known production methods such as open column chromatography using styrene-based adsorption resins such as HP-20 (manufactured by Mitsubishi Chemical Corporation), dextran-based resins such as Shephadex LH-20, and high-performance liquid chromatography (HPLC) are used. By using it, it is possible to isolate each compound of the formulas (I) to (IV) from such a mixture.
- the EGCG polymer used in the glucosyltransferase inhibitor of the present invention may be in the form of a salt.
- a salt is not particularly limited as long as it is a pharmaceutically or food acceptable salt, for example, a group of the periodic table such as lithium salt, sodium salt, potassium salt, calcium salt, and magnesium salt or Mention may be made of salts of Group 2 metal elements.
- Such metal salts can be formed, for example, at the phenolic hydroxyl group of EGCG.
- an EGCG trimer sodium salt is obtained by reacting an EGCG trimer with metallic sodium or sodium hydride in an aprotic solvent to convert a hydroxyl group (—OH) contained in the EGCG trimer to a sodium alkoxide group (— Can be produced by conversion to ONa).
- a hydroxyl group —OH
- a sodium alkoxide group — Can be produced by conversion to ONa.
- all of the hydroxyl groups contained in the EGCG trimer can be converted to sodium alkoxide groups, and only part of the hydroxyl groups are converted to sodium alkoxide groups. It can also be converted.
- the EGCG polymer which is an active ingredient of the GTF inhibitor of the present invention, is extracted and purified from teas using Camellia sinensis [A1] leaves, preferably fermented tea such as oolong tea and black tea, and roasted tea. It can also be isolated.
- EGCG polymers in particular oolong homobisflavan-trimer-1, which is a compound of the above formula (I), oolong homobisflavan-trimer-2, which is a compound of the formula (II), It was found that oolong homobisflavan-trimer-4 which is a compound of) and oolong homobisflavan-B which is a compound of formula (IV) have a high glucosyltransferase inhibitory action.
- the glucosyltransferase inhibitory action can be measured using any of the evaluation methods described in the prior art documents shown in the background art. For example, glucosyltransferase prepared from Streptococcus mutans or the like is added to an aqueous solution containing sucrose and incubated at a temperature similar to that in the oral cavity (about 37 ° C.) for less than 24 hours, preferably about 16 to 20 hours. Then, glucan is produced from sucrose by an enzymatic reaction. Since glucan is insoluble in water, the amount of glucan produced can be evaluated by measuring the turbidity (for example, turbidity at a wavelength of 550 nm) of the obtained reaction solution.
- turbidity for example, turbidity at a wavelength of 550 nm
- the glucosyltransferase inhibitor of the present invention can be used as an anti-cariogenic agent because it inhibits the activity of glucosyltransferase (GTF) to suppress the generation of glucan causing plaque in the mouth.
- GTF glucosyltransferase
- the glucosyltransferase inhibitor or anti-cariogenic agent of the present invention is derived from EGCG contained in foods and drinks that are eaten daily such as oolong tea, it has high palatability and high safety to the human body.
- the glucosyltransferase inhibitor or anti-cariogenic agent of the present invention can be added to various foods and drinks for the purpose of anti-caries such as caries prevention.
- foods and beverages to which the glucosyltransferase inhibitor or the anticaries agent of the present invention is added include soft drinks, tea drinks, liquid tonics, health drinks, nutritional drinks, sports drinks, carbonated drinks (concentrated concentrates of these drinks and Beverages (including preparation powder) and foods such as gums, candy, jelly, tablet confectionery, health foods, nutritional supplements, and supplements.
- the amount added to the food or drink is not particularly limited as long as the desired effect is obtained, and can be appropriately determined by considering the taste, color, fragrance and the like of the food and drink.
- the EGCG polymer when preparing a beverage intended for anti-caries, can be added to the beverage at a concentration of about 0.01 to 1000 ppm.
- the EGCG polymer when added to a solid food, about 0.01 to 5000 ⁇ g / g of EGCG polymer can be added with respect to the weight of the solid food.
- the glucosyltransferase inhibitor or anti-cariogenic agent of the present invention can suppress the production of glucan causing plaque in the mouth by inhibiting the activity of glucosyltransferase (GTF), prevention of dental caries and bad breath It can be used as an oral hygiene agent.
- the oral hygiene agent in the present invention include dentifrice, mouthwash, troche and the like.
- These oral hygiene agents can be produced by a conventional method using a carrier commonly used in the art.
- the carrier various organic or inorganic carrier substances that are commonly used as pharmaceutical materials can be used.
- formulation additives such as preservatives, antioxidants, colorants, sweeteners and the like can be blended as necessary.
- the amount of the GTF inhibitor or anti-cariogenic agent of the present invention added to the oral hygiene agent can be appropriately determined according to the form of the oral hygiene agent, etc. For example, about 0.0001 to 10% by weight in the oral hygiene agent
- the EGCG polymer can be contained so that the concentration becomes.
- Preparative HPLC conditions The fraction obtained by CHP-20P column purification was further purified by reverse phase preparative HPLC. ⁇ Conditions> Column: Develosil ODS-HG-5 (5 cm ⁇ ⁇ 50 cm, Nomura Chemical Co., Ltd.) Mobile phase: A: 0.05% TFA / H 2 O, B: 90% CH 3 CN / 0.05% TFA / H 2 O Flow rate: 32 ml / min Gradient program: Isocratic at A80% / B20% (30 min), gradient from A80% / B20% to A60% / B40% (100 min), isocratic at A60% / B40% (20 min) Detection: A280nm Sample: fr. Obtained by CHP-20P column purification. 2 to fr. 7 were each dissolved in 20% CH 3 CN, and the whole amount was loaded in several portions.
- One oolong homobisflavan-B (OHBF-B), compound 6 is a EGCG trimer with a binding mode of EGCG8: 8EGCG6: 8EGCG Oulon homobisflavan-trimer-1 (in this application, OHBF-Tri-1 Or Tri-1).
- the bond described as 6: 8 or 8: 8 between the above EGCGs represents a state in which the 6th or 8th carbon of the A ring of EGCG is bridged with a methylene group interposed therebetween.
- the structural formulas of the above compounds are shown below.
- the compounds 1 to 3 were subjected to structural analysis by the following MS and NMR.
- MS was measured in negative and V mode using ESI with a Z spray ion source attached to the ion source by Q-TOF Premier (manufactured by Micromass, UK).
- Cone volt. 45 V
- Capillary voltage 3 KV
- Desolation Temp 180 ° C.
- mass correction by rock spray was performed, and leucine enkephalin (m / z 554.2615 [MH] ⁇ ) was used as a reference.
- Compound 1 gives a molecular ion of m / z 1867.3100 [M ⁇ H] ⁇ and a divalent 933.1151 [M ⁇ 2H] 2 ⁇ , and has a molecular formula of C 91 H 72 O 44 (err .: ⁇ 11. 7 ppm), and it was estimated that the EGCG4 molecule was crosslinked by three methylenes.
- NMR was measured by dissolving Compound 2 in CD 3 OH and Compound 3 in DMSO-d6 ((CD 3 ) 2 SO).
- Compound 2 has CD 3 OH protons and 13 C residual peaks of ⁇ 3.30 and ⁇ 48.97 as internal standards, and Compound 3 is DMSO-d6 1 H of 2.50 ppm and 13 C residual peak of ⁇ 39. .43 was used as an internal standard.
- Measurement items were 1 HNMR, 13 CNMR, 1 H ⁇ 13 C ⁇ -HSQC, 1 H ⁇ 13 C ⁇ -HMBC, TOCSY, and DQF-COSY with DMX-750 spectrometer (BRUKER BIOSPIN, Germany).
- compound 2 is a compound of the above formula (II) having a binding mode of EGCG6: 8EGCG6: 8EGCG (that is, oolong homobisflavan-trimer-2, also referred to as OHBF-Tri-2 or Tri-2 in the present application).
- compound 3 is a compound of the above formula (III) having a binding mode of EGCG8: 8EGCG6: 6EGCG (ie, oolong homobisflavan-trimer-4, also referred to as OHBF-Tri-4 or Tri-4 in this application) ) Became clear.
- 1 HNMR and 13 CNMR spectra of compounds 2 and 3 are shown in FIGS.
- Compound 3 The 1 H NMR of oolong homobisflavan-trimer-4 (in DMSO-d6) is ⁇ 10.46, 9.18, 9.16, 9.16, 9.12, 9.06, 9.05, 8.90, 8.88, 8.84,8.72, 8.69, 8.69, 8.46, 8.34.
- Compound 1 was dissolved in DMSO-d6, and NMR measurement was performed using 1 H and 13 C residual peaks ⁇ 2.50 and ⁇ 39.43 as internal standards. Measurement items were 1 HNMR, 13 CNMR, 1 H ⁇ 13 C ⁇ -HSQC, 1 H ⁇ 13 C ⁇ -HMBC, TOCSY, and DQF-COSY with DMX-750 spectrometer (BRUKER BIOSPIN, Germany).
- compound 1 is an EGCG tetramer having a binding mode of EGCG8: 6EGCG8: 8EGCG6: 8EGCG (oolon homobisflavan-tetramer-2, also referred to as OHBF-Tet-2 or Tet-2 in this application). It became clear that.
- the 1 HNMR and 13 CNMR spectra of Compound 1 are shown in FIGS.
- Oolong homobisflavan-tetramer-2 has 1 HNMR (DMSO-d6) of ⁇ 9.91, 9.25, 9.16, 8.09, 7.22, 6.81, 6.76, 6.74, 6.52, 5.94, 5.50, 5.38, 4.77, 4.52, 3.95, 3.95, 3.80, 3.54, 2.80, 2.74, 2.73, 2.67 signals, 13 CNMR is ⁇ 165.08, 165.01, 154.06, 152.83, 152.35, 151.45, 150.78, 150.26, 145.52, 145.52, 145.24, 145.18, 138.49, 138.44, 132.21, 132.10, 128.42, 127.63, 119.05, 118.95, 108.58, 108.46, 108.46, 106.95, 105.74, 104.92, 104.06, 98.32, 97.81, 76.59, 75.94, 66.69, 66.
- rGTF Recombinant Glucosyltransferase
- rGTFB glucosyltransferase B
- rGTFC recombinant glucosyltransferase C
- RGTFB having a specific activity of 503 mU / mg protein was used, and rGTFC having a specific activity of 6.3 to 22.3 mU / mg protein was mixed and used.
- activity 1U indicates enzyme activity when 1.0 mM sucrose-derived glucose is converted to glucan in 1 minute.
- Protein quantification was performed using the bicinchoninic acid method (BCA method) (BCA protein assay kit, PIERCE).
- OHBF-A inhibited the activity of GTFB, but on the contrary, it was found that GTFC slightly enhanced the activity. In addition, it was found that TSN-A hardly affects the activity of GTFB, and that GTFC significantly increases the activity.
- OHBF-B and OHBF-Tri-1 were found to inhibit the activity of both GTFB and GTFC. In particular, OHBF-Tri-1 that is a trimer was found to most strongly inhibit the activities of both GTFB and GTFC compared to other compounds that are dimers.
- EGCG tetramer Tet-2 slightly inhibited the activity of GTFC, but no significant inhibitory effect was observed on GTFB.
- each of the EGCG trimers Tri-1, Tri-2, and Tri-4 has an inhibitory effect on GTFB and GTFC, and has a higher inhibitory activity on GTFB than Tet-2, which is an EGCG tetramer. It was.
- Tri-1, Tri-2, and Tri-4 which are EGCG trimers, and OHBF-B, which is an EGCG dimer, have a high GTF inhibitory action.
- the EGCG trimers Tri-1, Tri-2, and Tri-4 are the EGCG dimers OHBF-A, OHBF-B, and TSN-A, and the EGCG tetramer Tet. It was found to have a higher GTF inhibitory effect than -2.
- LC-MS / MS Quantification of Polymerized Polyphenols Trimer and tetramer LC-MS / MS measurement conditions and Suntory Black Oolong Tea LC-MS / MS measurement of EGCG polymer is 4000 Q TRAP (Applied) The measurement was performed under the following conditions using a turbo ion spray. Collision energy: 46 eV (nega.), Ionspray voltage: 4500 V, Temp: 450 ° C.
- the measurement channel in MRM (multiple reaction monitoring) of each compound is 698.40 / 168.90 (negative. Divalent) for oolong homobisflavan-trimers, and oolong homobisflavan-trimer-1 is used as a standard substance.
- Oolong homobisflavan-tetramer-2 was 933.16 / 168.90 (negative. Divalent), and oolong homobisflavan-tetramer-2 was used as a standard substance. The measurement was performed under the following measurement conditions.
- black oolong tea (before sterilization) was fractionated stepwise with a CHP-20P column (Mitsubishi Chemical Corporation), and after quantifying each fraction, the concentrations detected in each fraction were added together to determine the concentration in the tea. Concentration.
- the concentration in the black oolong tea was 172 ng / ml, which was the sum of the five components detected by trimmers in terms of oolong homobisflavan-trimer-1. Tetramers were the total of the four detected components, and were 55 ng / ml in terms of oolong homobisflavan-tetramer-2.
Abstract
Description
1. エピガロカテキンガレート3量体またはその塩を有効成分とするグルコシルトランスフェラーゼ阻害剤。
2. 前記エピガロカテキンガレート3量体が、クロマン環の6位および/または8位でメチレン基を介して結合した化合物である、上記1に記載のグルコシルトランスフェラーゼ阻害剤。
3. 前記エピガロカテキンガレート3量体が、次式(I):
5. エピガロカテキンガレート3量体またはその塩を有効成分とする抗う蝕剤。
6. 前記エピガロカテキンガレート3量体が、クロマン環の6位および/または8位でメチレン基を介して結合した化合物である、上記5に記載の抗う蝕剤。
7. 前記エピガロカテキンガレート3量体が、前記式(I)を有する化合物、前記式(II)を有する化合物、および前記式(III)を有する化合物(式(I)~(III)中、Rは前記式(A)で表されるガロイル基である)からなる群から選択される化合物である、上記6に記載の抗う蝕剤。
8. 前記式(IV)で表される化合物を有効成分とする抗う蝕剤。
9. 上記1~8のいずれかに記載のグルコシルトランスフェラーゼ阻害剤または抗う蝕剤を添加した飲食品。
10. 前記飲食品が茶飲料である、上記9に記載の飲食品。
11. 上記1~8のいずれかに記載のグルコシルトランスフェラーゼ阻害剤または抗う蝕剤を添加した口腔衛生剤。
(-)-エピカロカテキン-3-O-ガレート(EGCG)は、緑茶などの茶に含まれるカテキン類のうちの主要な成分の1つであり、次の式:
本発明者らにより、EGCG重合体、特に上記の式(I)の化合物であるウーロンホモビスフラバン-トリマー-1、式(II)の化合物であるウーロンホモビスフラバン-トリマー-2、式(III)の化合物であるウーロンホモビスフラバン-トリマー-4、および式(IV)の化合物であるウーロンホモビスフラバン-Bに高いグルコシルトランスフェラーゼ阻害作用がみられることが見出された。
本発明のグルコシルトランスフェラーゼ阻害剤または抗う蝕剤は、虫歯予防などの抗う蝕を目的として、各種飲食品に添加することができる。本発明のグルコシルトランスフェラーゼ阻害剤または抗う蝕剤を添加する飲食品の例としては、清涼飲料、茶飲料、液状強壮剤、健康飲料、栄養補給飲料、スポーツドリンク、炭酸飲料(これら飲料の濃縮原液および調製用粉末を含む)などの飲料や、ガム、キャンディー、ゼリー、錠菓、健康食品、栄養補給食品、サプリメントなどの食品が揚げられる。
本発明のグルコシルトランスフェラーゼ阻害剤または抗う蝕剤は、グルコシルトランスフェラーゼ(GTF)の活性を阻害することにより、口中で歯垢の原因となるグルカンの生成を抑えることができるため、虫歯予防および口臭予防などの口腔衛生剤に用いることができる。本発明における口腔衛生剤の例としては、歯磨、洗口液、トローチなどが挙げられる。これらの口腔衛生剤は、当業界で慣用される担体を用いて、慣用の手法で製造することができる。担体の例としては、製剤素材として慣用の各種有機または無機担体物質を用いることができる。また、必要に応じて、防腐剤、抗酸化剤、着色料、甘味剤などの製剤添加物を配合することもできる。本発明のGTF阻害剤または抗う蝕剤の口腔衛生剤への添加量は、口腔衛生剤の形態などに応じて適宜決定できるが、例えば、口腔衛生剤中に、0.0001~10重量%程度の濃度となるように、EGCG重合体を含有させることができる。
ア.合成とオープンカラムによる分画:
6gの(-)-エピガロカテキン-3-O-ガレート(EGCG)(ロッシュ社、Teavigo(登録商標))を0.02N HClを含む120mlのエタノールに溶解し、4%ホルムアルデヒドのエタノール溶液180mlを加え、室温で4時間、撹拌した。反応終了後、純水で10倍に希釈し、吸着樹脂CHP-20Pカラム(600ml、37-75μm、三菱化学株式会社)に負荷した。1200mlの水で洗浄後、900mlの25%CH3CN、1200mlの30%CH3CNで順次溶出し、25%CH3CN溶出画分は300mlずつ3フラクション(fr.1からfr.3)に分け、30%CH3CN溶出画分は300mlずつ4フラクション(fr.4からfr.7)に分画した。
CHP-20Pカラム精製で得られた分画物をさらに逆相の分取HPLCで精製した。
<条件>
カラム: Develosil ODS-HG-5(5cmφx50cm、野村化学株式会社)
移動相:A:0.05%TFA/H2O、B:90%CH3CN/0.05%TFA/H2O
流速:32ml/min
グラジエントプログラム:A80%/B20%でアイソクラティック(30min)、A80%/B20%からA60%/B40%へグラジエント(100min)、A60%/B40%でアイソクラティック(20min)
検出:A280nm
サンプル:CHP-20Pカラム精製で得られたfr.2からfr.7を、それぞれ20%CH3CNに溶解し、数回に分けて全量を負荷した。
分取HPLCで単離した化合物について、MSおよびNMR測定を行った。このうち、化合物4~6のMSをQ-TOF Premier(Micromass社製、UK)により、ネガティブ、Vモード測定したところ、それぞれm/z927.160、927.163、1397.248の[M-H]-のイオンピークが認められた。また、化合物4のNMRスペクトルデータは文献(Chem. Pharm. Bull 37(12), 3255-3563(1989))に記載のウーロンホモビスフラバン-AのNMRスペクトルデータと一致した。化合物5のNMRスペクトルデータは文献(Chem. Pharm. Bull 37(12), 3255-3563(1989))に記載のウーロンホモビスフラバン-BのNMRスペクトルデータと一致した。さらに、化合物6のNMRスペクトルデータから、化合物6は、上記の式(I)の化合物、すなわち、ウーロンホモビスフラバン-トリマー-1であることがわかった。これらの結果から、化合物4はEGCG8:8EGCGの結合様式を有するEGCG2量体であるウーロンホモビスフラバン-A(OHBF-A)であり、化合物5はEGCG6:8EGCGの結合様式を有するEGCG2量体であるウーロンホモビスフラバン-B(OHBF-B)であり、化合物6はEGCG8:8EGCG6:8EGCGの結合様式を有するEGCG3量体であるウーロンホモビスフラバン-トリマー-1(本願では、OHBF-Tri-1またはTri-1ともよぶ)であることが確認された。なお、上記のEGCG間の6:8または8:8と記した結合はEGCGのA環の6位または8位の炭素が間にメチレン基を挟んで架橋した状態を表す。上記の各化合物の構造式を以下に示す。
ウーロンホモビスフラバン-トリマー-2(CD3OH中)の1HNMRは、δ6.95, 6.92, 6.90, 6.60, 6.54, 6.44, 6.08, 6.02, 5.57, 5.55, 5.49, 5.18, 5.12, 4.91, 3.86, 3.83, 3.81, 3.76, 3.03, 3.01, 2.94, 2.89, 2.89, 2.82のシグナル、13CNMRは、δ 167.72, 167.46, 167.37, 156.29, 155.25, 155.08, 154.79, 154.43, 153.64, 152.91, 151.64, 151.20, 147.00, 146.93, 146.38, 146.38, 146.34, 146.29, 140.03, 139.89, 139.89, 134.65, 134.48, 133.85, 130.64, 129.29, 129.10, 121.33, 121.14, 121.14, 110.31, 110.24, 110.24, 109.19, 108.07, 107.42, 107.05, 107.02, 106.79, 106.10, 101.59, 101.00, 100.45, 97.23, 96.71, 80.07, 79.94, 78.45, 70.00, 69.32, 69.28, 27.21, 27.21, 26.81, 17.91, 17.91のシグナルが認められた。
ウーロンホモビスフラバン-トリマー-4(DMSO-d6中)の1HNMRは、δ10.46, 9.18, 9.16, 9.16, 9.12, 9.06, 9.05, 8.90, 8.88, 8.84,8.72, 8.69, 8.69, 8.46, 8.34, 8.05, 8.02, 8.00, 6.81, 6.78, 6.78, 6.52, 6.47, 6.35, 6.03, 5.93, 5.48, 5.46, 5.39, 5.04, 4.95, 4.89, 4.05, 3.95, 3.56, 3.56, 3.06, 3.00, 2.98, 2.76, 2.71, 2.67のシグナル、13CNMRは、δ165.11, 165.09, 164.99, 157.66, 154.29, 153.82, 153.48, 153.07, 152.68, 152.23, 152.18, 150.88, 145.56, 145.52, 145.50, 145.26, 145.24, 145.23, 138.43, 138.43, 138.39, 132.34, 132.23, 132.19, 128.34, 128.34, 128.23, 119.17, 119.12, 119.04, 110.35, 110.31, 110.29, 109.19, 108.59, 108.56, 108.51, 106.97, 106.63, 105.26, 105.26, 105.13, 104.73, 101.28, 99.44, 99.41, 98.21, 97.34, 97.15, 96.03, 79.48, 79.07, 78.47, 69.95, 69.39, 69.28, 27.18, 26.98, 26.58, 18.16, 17.13のシグナルが認められた。
ウーロンホモビスフラバン-テトラマー-2は1HNMR(DMSO-d6)は、δ9.91, 9.25, 9.16, 8.09, 7.22, 6.81, 6.76, 6.74, 6.52, 5.94, 5.50, 5.38, 4.77, 4.52, 3.95, 3.95, 3.80, 3.54, 2.80, 2.74, 2.73, 2.67のシグナル、13CNMRは、δ165.08, 165.01, 154.06, 152.83, 152.35, 151.45, 150.78, 150.26, 145.52, 145.52, 145.24, 145.18, 138.49, 138.44, 132.21, 132.10, 128.42, 127.63, 119.05, 118.95, 108.58, 108.46, 108.46, 106.95, 105.74, 104.92, 104.06, 98.32, 97.81, 76.59, 75.94, 66.69, 66.35,26.33, 25.26, 16.72, 15.99のシグナルが認められた。
rGTFを、論文M.matsumoto et al, FEMS Microbiology Letters 228 (2003) 73-80に記載の方法に準じて調製した。すなわち、Streptococcus mutansのグルコシルトランスフェラーゼB(GTFB)をコードする遺伝子を含むプラスミドpSK6を保有するEscherichia coli XL-2株を、アンピシリン100μg/mLおよびテトラサイクリン7.5μg/mL含有Luria Bertani液体培地中で37℃で16時間振盪培養した。培地を遠心分離して菌体を集め、菌体を冷却した10mMリン酸緩衝液(pH6.5)に懸濁した後、超音波発生機(UD201型、トミー精工、東京)で氷冷下で菌体を破砕した。破砕後、12,000x gで30分間遠心分離することにより沈査を取り除いた。得られた上清をリコンビナントグルコシルトランスフェラーゼB(rGTFB)として後の実験に用いた。
実施例1により得られたウーロンホモビスフラバンA(OHBF-A)、ウーロンホモビスフラバンB(OHBF-B)、およびウーロンホモビスフラバン-トリマー-1(Tri-1)、ならびに論文(Hashimoto, F. Nonaka, G. Nishioka, I. Chem. Pharm. Bull. 36 (5), 1676-1684 (1988))に準じて調製したテアシネンシンA(TSN-A)の各々についてのグルコシルトランスフェラーゼ(GTF)阻害作用を、以下の手順により評価した。なお、ここで比較として用いたテアシネンシンA(TSN-A)は、EGCGのB環の2’位同士が対称的に結合した物質であり、以下の構造を有する:
実施例1により得られたウーロンホモビスフラバン-トリマー-1(OHBF-Tri-1)、ウーロンホモビスフラバン-トリマー-2(OHBF-Tri-2)、ウーロンホモビスフラバン-トリマー-4(OHBF-Tri-4)、およびウーロンホモビスフラバン-テトラマー-2(OHBF-Tet-2)の各々についてのグルコシルトランスフェラーゼ(GTF)阻害作用を、以下の手順により評価した。
トリマーおよびテトラマーのLC-MS/MSの測定条件とサントリー黒烏龍茶の定量
EGCG重合物のLC-MS/MSの測定は、4000 Q TRAP(アプライド社製)で、ターボイオンスプレーを用い、以下の条件で測定した。Collision energy:46eV(nega.)、Ionspray voltage:4500V、Temp:450℃。
カラム:Develosil C30-UG-3(野村化学、3mmφ×150mm)
流速:0.3ml/min、
カラム温度:40℃
移動相A:0.1%HCOOH/H2O
移動相B:0.1%HCOOH/CH3CN
グラジエントプログラム:A91%/B9%(0min)→A40%/B60%(17min)→A15%/B85%(17.1min)、続いてA15%/B85%でアイソクラティック(17.1~19min)
これらの化合物は黒烏龍茶中に微量しか含まれないため、直接定量することは不可能であった。そこで、黒烏龍茶(殺菌前)をCHP-20Pカラム(三菱化学株式会社)でステップワイズに分画し、各フラクションの定量を行った後、各フラクションに検出された濃度を合算して茶中の濃度とした。黒烏龍茶中の濃度は、トリマー類は検出された5成分をウーロンホモビスフラバン-トリマー-1換算で合算し、172ng/mlであった。テトラマー類は検出された4成分を合算し、ウーロンホモビスフラバン-テトラマー-2換算で55ng/mlであった。
Claims (11)
- エピガロカテキンガレート3量体またはその塩を有効成分とするグルコシルトランスフェラーゼ阻害剤。
- 前記エピガロカテキンガレート3量体が、クロマン環の6位および/または8位でメチレン基を介して結合した化合物である、請求項1に記載のグルコシルトランスフェラーゼ阻害剤。
- エピガロカテキンガレート3量体またはその塩を有効成分とする抗う蝕剤。
- 前記エピガロカテキンガレート3量体が、クロマン環の6位および/または8位でメチレン基を介して結合した化合物である、請求項5に記載の抗う蝕剤。
- 請求項1~8のいずれかに記載のグルコシルトランスフェラーゼ阻害剤または抗う蝕剤を添加した飲食品。
- 前記飲食品が茶飲料である、請求項9に記載の飲食品。
- 請求項1~8のいずれかに記載のグルコシルトランスフェラーゼ阻害剤または抗う蝕剤を添加した口腔衛生剤。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES09809791.8T ES2619525T3 (es) | 2008-08-29 | 2009-08-14 | Inhibidor de la glucosiltransferasa que contiene un polímero de galato de epigalocatequina como principio activo |
CN2009801339636A CN102137853B (zh) | 2008-08-29 | 2009-08-14 | 以表没食子儿茶素没食子酸酯聚合物为有效成分的葡糖基转移酶抑制剂 |
US13/061,073 US9237996B2 (en) | 2008-08-29 | 2009-08-14 | Glucosyltransferase inhibitor containing epigallocatechin gallate polymer as active ingredient |
EP09809791.8A EP2330104B1 (en) | 2008-08-29 | 2009-08-14 | Glucosyltransferase inhibitor containing epigallocatechin gallate polymer as active ingredient |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008-222851 | 2008-08-29 | ||
JP2008222851A JP5563753B2 (ja) | 2008-08-29 | 2008-08-29 | エピガロカテキンガレート重合体を有効成分とするグルコシルトランスフェラーゼ阻害剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010024138A1 true WO2010024138A1 (ja) | 2010-03-04 |
Family
ID=41721307
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/064335 WO2010024138A1 (ja) | 2008-08-29 | 2009-08-14 | エピガロカテキンガレート重合体を有効成分とするグルコシルトランスフェラーゼ阻害剤 |
Country Status (7)
Country | Link |
---|---|
US (1) | US9237996B2 (ja) |
EP (1) | EP2330104B1 (ja) |
JP (1) | JP5563753B2 (ja) |
CN (1) | CN102137853B (ja) |
ES (1) | ES2619525T3 (ja) |
TW (1) | TWI492765B (ja) |
WO (1) | WO2010024138A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020103133A (ja) * | 2018-12-27 | 2020-07-09 | 太陽化学株式会社 | 歯垢形成予防剤 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI469779B (zh) * | 2008-08-29 | 2015-01-21 | Suntory Holdings Ltd | Novel epigallocatechin gallate 4, and its vascular endothelial function enhancer |
CN105342863B (zh) * | 2015-12-11 | 2018-08-24 | 张凌 | 表没食子儿茶素没食子酸脂在提高牙科树脂粘接材料修复方面的应用 |
TW202037634A (zh) | 2019-01-24 | 2020-10-16 | 日商住友精化股份有限公司 | 脂肪族聚碳酸酯 |
CN109879850B (zh) * | 2019-02-26 | 2021-01-05 | 中国农业科学院茶叶研究所 | 一种制备三种聚酯型儿茶素单体的方法 |
CN114763551B (zh) * | 2021-12-07 | 2023-09-15 | 西藏自治区农牧科学院农业研究所 | 一种青稞矢车菊素糖基转移酶基因及其用途 |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03284671A (ja) | 1990-03-30 | 1991-12-16 | Suntory Ltd | グルコシルトランスフェラーゼ阻害活性の増強方法 |
JPH03284625A (ja) | 1990-03-30 | 1991-12-16 | Suntory Ltd | 抗う蝕性物質の製造法及びその用途 |
JPH06247959A (ja) | 1993-02-24 | 1994-09-06 | Suntory Ltd | フラボノイド重合物およびこれを有効成分とするグルコシルトランスフェラーゼ阻害剤 |
JPH06279302A (ja) | 1990-03-30 | 1994-10-04 | Suntory Ltd | 抗う蝕剤および抗う蝕性食品並びに抗う蝕性物質の製造方法 |
JPH07242556A (ja) | 1994-03-08 | 1995-09-19 | Suntory Ltd | 抗う蝕性フラボノイド重合物およびこれを有効成分とするグルコシルトランスフェラーゼ阻害剤並びに食品 |
JPH07285876A (ja) * | 1993-12-06 | 1995-10-31 | Nikka Uisukii Kk | 果実ポリフェノールとその製造方法、酸化防止剤、血圧降下剤、抗変異原性作用剤、アレルギー抑制剤、抗う蝕剤及び消臭剤 |
JP2004244385A (ja) * | 2003-02-14 | 2004-09-02 | Pigeon Corp | 防齲蝕性を有する乳幼児用の口腔内洗浄液 |
JP2005154432A (ja) * | 2003-11-05 | 2005-06-16 | Nichirei Corp | ポリフェノールおよび/またはビタミンcを含有するアセロラ処理物 |
JP2005336117A (ja) * | 2004-05-27 | 2005-12-08 | Suntory Ltd | リパーゼ阻害活性および/または抗酸化活性を有するエピガロカテキン二量体および三量体 |
JP2007176845A (ja) * | 2005-12-27 | 2007-07-12 | Meiji Yakuhin Kk | 柿ポリフェノール |
JP2008517069A (ja) * | 2004-10-19 | 2008-05-22 | ユニゲン・ファーマシューティカルス・インコーポレーテッド | 口腔疾患および状態の予防または処置に用いるための二重エイコサノイド系・サイトカイン系阻害剤の製剤 |
JP2009001531A (ja) * | 2007-06-22 | 2009-01-08 | Meiji Yakuhin Kk | 柿ポリフェノールオリゴマー |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6011912B2 (ja) | 1981-07-30 | 1985-03-28 | 日本新薬株式会社 | タンニン |
JPH01102022A (ja) | 1987-10-14 | 1989-04-19 | Advance Co Ltd | 肥満予防剤 |
JP2975380B2 (ja) | 1989-08-30 | 1999-11-10 | 三井農林株式会社 | プラーク形成阻害剤 |
JPH03201947A (ja) * | 1989-12-29 | 1991-09-03 | Ajinomoto Co Inc | デザート類食品 |
JPH03219872A (ja) | 1990-01-25 | 1991-09-27 | Meiji Seika Kaisha Ltd | リパーゼ阻害剤 |
JPH03228664A (ja) | 1990-02-02 | 1991-10-09 | Meiji Seika Kaisha Ltd | 脂質の消化吸収抑制機能を有する食品 |
ES2077703T3 (es) * | 1990-03-30 | 1995-12-01 | Suntory Ltd | Inhibidores de la glucosiltransferasa, asi como metodos para la prevencion de la caries dental y alimentos anticaries que utilizan estos inhibidores. |
JP2598873B2 (ja) | 1993-08-25 | 1997-04-09 | 株式会社ロッテ | リパーゼ阻害剤およびこれを添加した飲食品 |
CA2128293C (en) * | 1993-12-06 | 2002-09-03 | Masayuki Tanabe | Fruit polyphenols and medicinal compositions containing them |
JP3532999B2 (ja) * | 1995-03-24 | 2004-05-31 | 株式会社ロッテ | 新規なタンニン類およびこれを有効成分とするリパーゼ阻害剤 |
JP3828953B2 (ja) | 1995-05-24 | 2006-10-04 | 日本製粉株式会社 | リパーゼ阻害剤 |
EP0815857B1 (en) * | 1995-12-26 | 2004-09-29 | Suntory Limited | Antiobestic agent containing procyanidin as the active ingredient |
JP2926471B2 (ja) * | 1996-01-19 | 1999-07-28 | 義郎 中松 | 交通事故防止等用飴 |
JPH10175874A (ja) * | 1996-12-19 | 1998-06-30 | Suntory Ltd | 抗アレルギー剤 |
JP4507027B2 (ja) | 1998-12-04 | 2010-07-21 | 明治乳業株式会社 | Mmp阻害剤 |
US8945518B2 (en) * | 2002-04-30 | 2015-02-03 | Unigen, Inc. | Formulation of dual eicosanoid system and cytokine system inhibitors for use in the prevention and treatment of oral diseases and conditions |
EP2193723A4 (en) * | 2007-09-11 | 2013-09-11 | Suntory Holdings Ltd | FOOD OR BEVERAGE WITH IMPROVED SWEETMARK |
CN102137662B (zh) * | 2008-08-29 | 2017-02-08 | 三得利控股株式会社 | 含有新型表没食子儿茶素没食子酸酯三聚体及表没食子儿茶素没食子酸酯聚合物的α‑葡萄糖苷酶抑制剂 |
-
2008
- 2008-08-29 JP JP2008222851A patent/JP5563753B2/ja active Active
-
2009
- 2009-08-14 WO PCT/JP2009/064335 patent/WO2010024138A1/ja active Application Filing
- 2009-08-14 EP EP09809791.8A patent/EP2330104B1/en active Active
- 2009-08-14 US US13/061,073 patent/US9237996B2/en not_active Expired - Fee Related
- 2009-08-14 ES ES09809791.8T patent/ES2619525T3/es active Active
- 2009-08-14 CN CN2009801339636A patent/CN102137853B/zh active Active
- 2009-08-24 TW TW098128375A patent/TWI492765B/zh active
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03284671A (ja) | 1990-03-30 | 1991-12-16 | Suntory Ltd | グルコシルトランスフェラーゼ阻害活性の増強方法 |
JPH03284625A (ja) | 1990-03-30 | 1991-12-16 | Suntory Ltd | 抗う蝕性物質の製造法及びその用途 |
JPH06279302A (ja) | 1990-03-30 | 1994-10-04 | Suntory Ltd | 抗う蝕剤および抗う蝕性食品並びに抗う蝕性物質の製造方法 |
JPH06247959A (ja) | 1993-02-24 | 1994-09-06 | Suntory Ltd | フラボノイド重合物およびこれを有効成分とするグルコシルトランスフェラーゼ阻害剤 |
JPH07285876A (ja) * | 1993-12-06 | 1995-10-31 | Nikka Uisukii Kk | 果実ポリフェノールとその製造方法、酸化防止剤、血圧降下剤、抗変異原性作用剤、アレルギー抑制剤、抗う蝕剤及び消臭剤 |
JPH07242556A (ja) | 1994-03-08 | 1995-09-19 | Suntory Ltd | 抗う蝕性フラボノイド重合物およびこれを有効成分とするグルコシルトランスフェラーゼ阻害剤並びに食品 |
JP2004244385A (ja) * | 2003-02-14 | 2004-09-02 | Pigeon Corp | 防齲蝕性を有する乳幼児用の口腔内洗浄液 |
JP2005154432A (ja) * | 2003-11-05 | 2005-06-16 | Nichirei Corp | ポリフェノールおよび/またはビタミンcを含有するアセロラ処理物 |
JP2005336117A (ja) * | 2004-05-27 | 2005-12-08 | Suntory Ltd | リパーゼ阻害活性および/または抗酸化活性を有するエピガロカテキン二量体および三量体 |
WO2005116005A1 (ja) | 2004-05-27 | 2005-12-08 | Suntory Limited | リパーゼ阻害活性および/または抗酸化活性を有するエピガロカテキン二量体および三量体 |
JP2008517069A (ja) * | 2004-10-19 | 2008-05-22 | ユニゲン・ファーマシューティカルス・インコーポレーテッド | 口腔疾患および状態の予防または処置に用いるための二重エイコサノイド系・サイトカイン系阻害剤の製剤 |
JP2007176845A (ja) * | 2005-12-27 | 2007-07-12 | Meiji Yakuhin Kk | 柿ポリフェノール |
JP2009001531A (ja) * | 2007-06-22 | 2009-01-08 | Meiji Yakuhin Kk | 柿ポリフェノールオリゴマー |
Non-Patent Citations (10)
Title |
---|
CHEM. PHARM. BULL, vol. 37, no. 12, 1989, pages 3255 - 3563 |
FUMIO HASHIMOTO ET AL.: "Tannins and Related Compounds. XC. : 8-C-Ascorbyl (-)- Epigallocatechin 3-O-Gallate and Novel Dimeric Flavan -3-ols, Oolonghomobisflavans A and B, from Oolong Tea. (3)", CHEM. PHARM. BULL., vol. 37, no. 12, 1989, pages 3255 - 3263, XP000654502 * |
HAMADA S., FEMS MICROBIOLOGY LETTERS, vol. 143, 1996, pages 35 - 40 |
HASHIMOTO, F. NONAKA; G. NISHIOKA, I., CHEM. PHARM. BULL., vol. 36, no. 5, 1988, pages 1676 - 1684 |
M. MATSUMOTO ET AL., FEMS MICROBIOLOGY LETTERS, vol. 228, 2003, pages 73 - 80 |
MATSUMOTO M., FEMS MICROBIOLOGY LETTERS, vol. 228, 2003, pages 73 - 80 |
NAKAHARA K., APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 59, no. 4, 1993, pages 968 - 973 |
OOSHIMA T.; HAMADA S., THE NIPPON DENTAL REVIEW, no. 622, August 1994 (1994-08-01), pages 179 - 189 |
OTAKE S., CARIES RES., vol. 25, 1991, pages 438 - 443 |
See also references of EP2330104A4 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020103133A (ja) * | 2018-12-27 | 2020-07-09 | 太陽化学株式会社 | 歯垢形成予防剤 |
JP7345250B2 (ja) | 2018-12-27 | 2023-09-15 | 太陽化学株式会社 | 歯垢形成予防剤 |
Also Published As
Publication number | Publication date |
---|---|
EP2330104B1 (en) | 2017-03-01 |
US20110150790A1 (en) | 2011-06-23 |
TW201014837A (en) | 2010-04-16 |
JP5563753B2 (ja) | 2014-07-30 |
US9237996B2 (en) | 2016-01-19 |
CN102137853A (zh) | 2011-07-27 |
CN102137853B (zh) | 2013-11-06 |
ES2619525T3 (es) | 2017-06-26 |
EP2330104A1 (en) | 2011-06-08 |
JP2010053110A (ja) | 2010-03-11 |
TWI492765B (zh) | 2015-07-21 |
EP2330104A4 (en) | 2011-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7989492B2 (en) | Epigallocatechin dimers or trimers having lipase inhibitory activity and/or antioxidant activity | |
TWI469779B (zh) | Novel epigallocatechin gallate 4, and its vascular endothelial function enhancer | |
WO2010024138A1 (ja) | エピガロカテキンガレート重合体を有効成分とするグルコシルトランスフェラーゼ阻害剤 | |
RU2433824C2 (ru) | Продукты присоединения сахаров к флавоноидам, способ их получения и применение | |
TWI529165B (zh) | Novel epigallocatechin gallate 3-mer, and the use of alpha-glucosidase inhibitors containing epigallocatechin gallate polymers | |
JPWO2003094878A1 (ja) | ガロカテキンガレート含有組成物 | |
US7939116B2 (en) | Sulfur-containing proanthocyanidin oligomer composition and production method thereof | |
TW201109018A (en) | Anti-obesity agent comprising compound containing benzotropolone ring | |
JP6347734B2 (ja) | 茶由来シクロオキシゲナーゼ−2阻害剤 | |
KR20180042795A (ko) | 신규한 퀘르세틴계 화합물을 포함하는 인지기능 개선용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980133963.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09809791 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13061073 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2009809791 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009809791 Country of ref document: EP |